Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer
Conclusions: Pancreatic carcinoma is an aggressive malignancy typically associated with severe hyperglycemia. Furthermore, hyperglycemia is one of the severe ADRs from antineoplastics, which must be paid special attention to when treating in pancreatic carcinoma, especially doxorubicin, fluorouracil, and gemcitabine. Such real-time monitoring or pretreatment gene test can be suggested.
Source: Nigerian Journal of Clinical Practice - Category: Rural Health Authors: J Yang B Jia J Yan J He Source Type: research
More News: Alimta | Cancer | Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Genetics | Nigeria Health | Nutrition | Pancreas | Pancreatic Cancer | Rural Health